Shanghai Henlius says first US patient dosed in Phase 1 trial of ipilimumab biosimilar HLX13 for advanced liver cancer

  • Shanghai Henlius Biotech reported first US patient dosed in an international Phase 1 study of HLX13, an ipilimumab biosimilar, in first-line unresectable advanced liver cancer.
  • No results have been presented; the trial will generate comparative data on how HLX13 performs versus Yervoy when paired with Opdivo.
  • Study aims to support biosimilar positioning by assessing whether HLX13 matches the reference drug’s overall clinical profile in this setting.
  • Henlius licensed US and other major-market commercialization rights for HLX13 to Sandoz in April 2025, setting a partnered route to market.
  • Global ipilimumab sales totaled about USD 3.28 billion in 2025, underscoring the product’s commercial opportunity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260625-12215212), on June 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.